Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Oncology > ESMO 2019 > Lung Cancer > Mixed data: AMG 510 in tumours with KRASG12C

Mixed data: AMG 510 in tumours with KRASG12C

Presented by
Prof. Ramaswamy Govindan, Washington University, St Louis, USA
Conference
ESMO 2019
    The ongoing phase 1 study evaluating investigative drug AMG 510 in patients with previously treated KRAS G12C-mutant solid tumours (KRASG12C) was presented by Prof. Ramaswamy Govindan (Washington University, St Louis, USA) [1]. The data include the first evidence of anti-tumour activity reported in patients with colorectal cancer (CRC) and appendiceal cancer, as well as previously presented non-small cell lung cancer (NSCLC) findings. AMG 510 continues to be well-tolerated with no dose-limiting toxicities.

    This first-in-human, open-label, multicentre study enrolled 76 patients with KRASG12C-mutant solid tumours. Eligible patients were heavily pre-treated with at least two prior lines of treatment. The primary endpoint was safety, and key secondary endpoints include pharmacokinetics, objective response rate (assessed every 6 weeks), duration of response, and progression-free survival. Patients were enrolled in 4 dose cohorts: 180 mg, 360 mg, 720 mg, and 960 mg, taken orally once daily.

    A subset of 55 evaluable patients as of the July 2019 data cut-off were presented, including CRC, appendiceal cancer, and NSCLC patients. Of these, 29 had CRC, 12 of whom received the target dose of 960 mg once daily (see Figure). Only 1 patient in this dose cohort experienced a partial response, and 10 had stable disease for a disease control rate of 92%. Of the evaluable patients with NSCLC, 13 received 960 mg, of which 7 (54%) achieved a partial response at one or more timepoints and 6 (46%) achieved stable disease, for a disease control rate of 100%. Data across dosing cohorts also showed tumour responses in 2 evaluable patients with appendiceal cancer with 1 partial response and 1 experiencing stable disease.

    Figure. Change in colorectal (CRC) tumour burden after treatment with AMG 510.



    Figure provided by ESMO.

    Among the 76 patients enrolled across treatment groups, 52 remain on treatment. The majority of treatment-related adverse events (AEs) were grade 1 and 2. Only two treatment-related AEs were grade 3 (diarrhoea and anaemia). Thus, although the primary endpoint of safety was met, the single partial response in the CRC cohort was disappointing with regard to efficacy, despite better response in NSCLC.

    1. Govindan R et al. ESMO Congress 2019. Abstract 446PD.




    Posted on